Open AccessEffectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer
Author(s) -
JoHsuan Wu,
JinYuan Shih
Publication year - 2016
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s118071
Subject(s) - t790m , erlotinib , gefitinib , epidermal growth factor receptor , exon , medicine , lung cancer , tyrosine kinase , mutation , cancer research , oncology , erlotinib hydrochloride , cancer , biology , receptor , gene , genetics
Clinical features of epidermal growth factor receptor (EGFR) mutations: L858R, deletions in exon 19, T790M, insertions in exon 20, G719X, and L861X in non-small-cell lung cancer (NSCLC) are well-known. The clinical significance of other uncommon EGFR mutations, such as E709X, is not well understood. This study aimed to improve the understanding of E709X, and the clinical response to tyrosine kinase inhibitors (TKIs) of NSCLC patients with such an uncommon mutation.